Month: April 2018
-
Lilly, Cell Implants Start-Up Partner on Diabetes
Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases.
-
Hydrogel, Solar Power Provide Simple Water Purification
An engineering lab demonstrates how polymer gels and ambient sunlight can provide a simple, inexpensive alternative to current complex and expensive technologies for desalinating or purifying drinking water.
-
Packaging Up Your Solution
Today, the most powerful medium for any type of commercial practice is a website; your website must show the problem you solve and why you are relevant to your target audience.
-
New Company Acquires Off-the-Shelf T-Cell Cancer Therapies
A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells.
-
Cough Suppressant Produced from Engineered Yeast Cells
A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast.
-
Nanotech Pain Drug Formulations Developed
A pharmaceutical researcher developed treatments for chronic pain, formulated as nanoscale droplets, that in tests with lab animals target the source of pain directly and use much smaller doses than current pain drugs.
-
Antibodies Licensed for Multi-Target Immunotherapies
MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets.